CBLL · CIK 0001861107
What Ceribell, Inc. told the SEC could break it.
Ceribell's results rest on a single product: it expects the Ceribell System to keep accounting for almost all of its revenue, so its fortunes track that one EEG platform's market acceptance against conventional and alternative systems. The product's demand also depends on reimbursement — substantially all revenue comes from U.S. hospitals and providers who bill third-party payers including private insurers, Medicare and Medicaid, so an adverse coverage decision would directly impair sales. On the supply side, it leans on two primary contract manufacturers in China (with Vietnam assembly) for its Wearables and a significant share of components, concentrating its supply chain offshore and exposing it to the 2025 U.S. tariffs on Chinese and Vietnamese imports.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- dependence on third-party payer (Medicare/Medicaid/private) reimbursementmedium
Ceribell derives substantially all revenue from U.S. hospitals and providers who in turn bill third-party payers (private insurers, Medicare, Medicaid); adverse coverage or reimbursement decisions would directly impair demand for the Ceribell System.
“We derive substantially all of our revenue from healthcare providers and hospitals that use the Ceribell System in the United States. These facilities and providers, in turn, bill third-party payers, including private insurers, Medicare, and Medicaid, for the services and items they provide to patients.”
SEC filing →As of 2026 - 2025 U.S. tariffs on China/Vietnam imports (Wearables & components)low
2025 U.S. tariffs on imports from China, Vietnam and other regions — and retaliatory measures — create cost and supply uncertainty for the offshore-manufactured Wearables and components central to the Ceribell System.
“In 2025, the U.S. imposed additional tariffs on imports from China, Vietnam, and other regions and announced and subsequently paused implementation of certain tariffs. These actions and related retaliation have created significant market uncertainty and may affect the prices of and demand for our products, negatively impacting our results of operations.”
Other disclosures
- single-product concentration (Ceribell System ≈ all revenue)medium
Almost all of Ceribell's revenue comes from the single Ceribell System product line; failure to sustain market acceptance, or successful competition from conventional/alternative EEG systems, would materially harm the business.
“We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.”
SEC filing →As of 2026
Supplier concentration
- two primary contract manufacturers in China for Wearables; China/Vietnam assemblymedium
Ceribell relies on two primary contract manufacturers in China (plus Vietnam) for primary assembly and inspection of its Wearables and a significant portion of components; this concentration exposes it to supply shortages, quality issues, and U.S.–China geopolitical/economic risk.
“We rely on two primary contract manufacturers in China and maintain contractors in China who perform monitoring and quality inspection services.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
The Board of Trustees of the Leland Stanford Junior University
“On June 12, 2025, the Company paid the option exercise fee of $250,000 to extend the exclusivity of the license from Stanford until the date the last expiry of the licensed patents, which is in May 2036.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch